Dozens of coronavirus drugs are in development — what happens next? (Nature)

Drug manufacturers face supply-chain weaknesses and sourcing issues as they ramp up complex production processes to meet global demand.
“Over the past two decades, manufacturers in many different industries have been shifting to a ‘lean’ manufacturing model that reduces the amount of raw materials and finished product they keep in stock. “This was successful in terms of reducing costs,” Simchi-Levi says. “But it increased exposure to risk.”

Read the Story